Corxel secures $300M financing to advance oral obesity drugs
Corxel US has agreed to merge with Amanat Acquisition Corp in a $377 million business combination that will support the development of its oral obesity drug candidates, including Phase 2-stage GLP-1 agonist CX11.
The proposed transaction includes approximately $300 million in private investment in public equity (PIPE) commitments and is expected to fund the company’s operations through 2029, including its planned global Phase 3 programme for CX11.
The deal is expected to close in the first half of 2027, subject to shareholder and regulatory approvals and other customary closing conditions.
Oral GLP-1 candidate leads development programme
Corxel US is developing oral therapies for obesity and related cardiometabolic conditions, with CX11 as its lead clinical candidate.
CX11 is an investigational, once-daily, small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has demonstrated weight loss in Phase 2 studies in the US and clinical development programmes in Asia.
In a US Phase 2 obesity trial, CX11 achieved mean body-weight reduction of up to 11.5% at Week 36, based on the efficacy estimand.
The 36-week study also reported a generally favourable gastrointestinal tolerability profile. Nausea occurred in 33–34% of participants across dosing cohorts, while vomiting was reported in 12–16%, diarrhoea in 4–12% and constipation in 2–12%.
Most gastrointestinal adverse events were mild to moderate and occurred primarily during dose escalation. Treatment discontinuation due to gastrointestinal adverse events was 5%.
Following an End-of-Phase 2 meeting, Corxel US said it had aligned with the US Food and Drug Administration (FDA) on key elements of CX11’s regulatory pathway and Phase 3 trial design.
The company plans to advance the candidate into global Phase 3 development.
An ongoing Phase 1b study investigating higher doses of CX11 is expected to provide additional data in the first half of 2027.
Amylin programme adds to oral obesity pipeline
Corxel US is also developing CX12, an investigational oral small-molecule amylin receptor agonist.
Several lead candidates are under evaluation, with investigational new drug (IND)-enabling activities under way. The company is targeting an IND application in the first half of 2027.
Amylin is a hormone involved in appetite regulation and glucose metabolism, making its receptor an additional target of interest in obesity and metabolic disease drug development.
The two candidates represent different approaches to oral treatment, with CX11 targeting GLP-1 receptors and CX12 targeting amylin receptors.
$377M transaction to fund development through 2029
The proposed business combination with Amanat Acquisition Corp is expected to provide approximately $377 million in gross proceeds, comprising around $300 million from the PIPE financing and approximately $75 million held in Amanat’s trust account.
The PIPE has attracted commitments from new and existing investors, including RTW Investments, New Enterprise Associates, SR One, Mirae Asset Capital Life Science, HBM Healthcare Investments, RA Capital Management and TCGX.
The financing is expected to support the combined company’s operations through 2029 and fund CX11’s planned global Phase 3 programme.
Under the agreement, Corxel US will become a wholly owned subsidiary of the combined public company, which is expected to trade on the Nasdaq Capital Market under a new name and ticker symbol.
Sandy Mou, CEO of Corxel Group, said: “This transaction represents another important milestone in Corxel Group’s corporate evolution and reflects the significant progress we have made in building a globally competitive cardiometabolic pipeline.”
The transaction covers Corxel US and the obesity-focused assets included in the agreement. Other Corxel Group businesses and assets, including the acute ischaemic stroke programme JX10 held by Corxel HK, will remain outside the proposed public company.
The boards of Corxel US and Amanat have approved the agreement. Completion remains subject to shareholder approval, regulatory requirements and other closing conditions, with the companies targeting the first half of 2027.




